

# Myriad™

## Application Notes

### Myriad Matrix™ & Myriad Morcells™

Soft Tissue Bioscaffold

Morcellized Bioscaffold




Unlocking regenerative healing for everybody

### Contents

<b>Myriad portfolio for soft tissue repair</b>	<b>3</b>
<b>General</b>	<b>4</b>
<b>Preparation of the site</b>	<b>4</b>
<b>Product selection</b>	<b>4</b>
<b>Preparing Myriad Morcells</b>	<b>5</b>
<b>Preparing Myriad Matrix</b>	<b>5</b>
<b>Dressing selection</b>	<b>7</b>
<b>Dressing changes</b>	<b>8</b>
<b>What to expect on placement of the device</b>	<b>9</b>
<b>Device appearance and integration in a soft tissue defect</b>	<b>10</b>
Early timepoints (<14 days)	<b>10</b>
Later timepoints (>14 days)	<b>12</b>
<b>Residual Myriad</b>	<b>12</b>
<b>Moist wound environment</b>	<b>14</b>
<b>Myriad Morcells may persist in the wound bed</b>	<b>14</b>
<b>Debridement during the course of Myriad healing</b>	<b>15</b>
<b>Definitive closure</b>	<b>15</b>
<b>Bibliography</b>	<b>16</b>

## Myriad™ | Portfolio for Soft Tissue Repair



### Myriad Matrix™

Available as 2-, 3- or 5-layers of non-crosslinked AROA ECM™




For **soft tissue reconstruction, reinforcement** or **complex wounds**

### Myriad Morcells™

Morcellised AROA ECM

For **management of acute and chronic wounds**, including closed surgical wounds

**Myriad Morcells** is not intended for implantation



### General

Always read the **Instructions For Use**. Prescription use only. The following guidelines should not supersede professional or institutional guidelines. These guidelines have been developed based on good surgical technique and the experience of surgeons. The guidelines are intended to be a quick reference to important information on the use of **Myriad Matrix™** and **Myriad Morcells™**. For additional information contact your Sales Representative or [www.aroabio.com](http://www.aroabio.com).

### Preparation of the Site

Prepare the wound bed by cleansing, irrigation and, if necessary, sharp or ultrasonic debridement to ensure the wound is free of debris, necrotic tissue or infected tissue.



If the tissue defect has been irrigated with antiseptic solutions (e.g. hypochlorous acid, sodium hypochlorite, Povidone-iodine, chlorhexidine gluconate) it is recommended to rinse the area with sterile saline prior to application of **Myriad** products. Antiseptic solutions may damage the structure and extracellular matrix (ECM) components found in **Myriad** products.

Ideally the tissue deficit will have healthy and well vascularised tissue to optimise the incorporation of **Myriad** devices. Do not apply **Myriad** devices in the presence of uncontrolled clinical infection.



Wound bed contamination is known to limit the use of certain dermal matrices due to high rates of infection.<sup>[1-3]</sup> Myriad products have been shown to be relatively resistant to bacterial contamination and may be used in contaminated soft tissue defects without having to wait till a pristine wound bed is achieved.<sup>[4-6]</sup>

Where exposed bone is present, including calvarium, and denuded of the vascularised periosteum, a burr or drill attachment may be used to expose the vascular diploe. **Myriad** devices can then be applied to the bleeding calvarium or bone.

### Product Selection

Consider using **Myriad Morcells** in soft tissue defects with irregular, undermined or tunneled areas.

**Myriad Matrix** is available in 2-layer, 3-layer and 5-layer configurations. Thicker configurations of **Myriad Matrix** may persist longer in the wound. Consider using;

- 2-Layer and 3-layer configurations in superficial and partial-thickness defects.
- 3-Layer and 5-layer for deep-partial and full thickness defects with, or without, exposed structures.




**Myriad Morcells** and **Myriad Matrix** may be used in combination. Consider using both **Myriad** devices in instances of significant volumetric tissue loss.



## Preparing Myriad Morcells

- 1) **Myriad Morcells** are supplied in a sterile tray. **Myriad Morcells** may be poured directly from the tray into the soft tissue deficit, then rehydrate in the soft tissue defect. Alternately, **Myriad Morcells** can be rehydrated with sterile saline and then transferred to the defect.
- 2) Apply **Myriad Morcells** throughout the wound bed, and especially to areas with an irregular surface or depth to achieve a more planar surface (Figure 1).

Figure 1. Representative images showing application of **Myriad Morcells**.



- 3) **Myriad Morcells** may be packed into tunneled or undermined areas of the wound.



Consider using **Myriad Matrix** to bolster the **Myriad Morcells** to the soft tissue deficit (Figure 4).

## Preparing Myriad Matrix




Prior to and during rehydration of the device it is important to limit excessive handling to preserve the engineered multi-layer structure of the device.

- 1) Once removed from the packaging using aseptic technique, place the **Myriad Matrix** device in a shallow sterile bowl or basin, ensuring that the container is larger than the device, so the device can lie flat during rehydration.
- 2) Add sufficient sterile saline to cover the device and rehydrate.



As the device rehydrates you may notice a change in the appearance of the device, from white to opaque (Figure 2).

Figure 2




Do not rehydrate **Myriad** devices in antiseptic solutions (e.g. hypochlorous acid, sodium hypochlorite, Povidone-iodine, chlorhexidine gluconate) as these chemical disinfectants may damage the structure or ECM components.




Always use aseptic technique e.g. avoid placing the device on linting surfaces (e.g. surgical drapes, back table drapes) as lint fibers may contaminate the device and have been known to increase rates of infection.<sup>[7, 8]</sup>

- 3) Trim the **Myriad** device to fit, if necessary, providing an allowance for overlap. Position the device to achieve maximum contact between the device and prepared wound surface. It is recommended to suture, or staple the device in place, avoiding excess tension (Figure 3). Fixing the device in place helps to ensure intimate contact with the underlying wound bed and reduces movement of the device during the healing process. Also, consider bolster staples or sutures to the central part of the device to further ensure intimate and sustained contact to the underlying tissue.

Figure 3. Examples of **Myriad Matrix** surgical fixation.



Stapled to the wound perimeter of the foot plantar.



Sutured to wound perimeter on axilla. Tacked down with interrupted absorbable sutures in central portion.



Multiple devices may be sutured together.

## Dressing Selection

**Myriad** products may be used with a range of primary and secondary dressings.




Figure 4.  
Use of **Myriad** products with  
primary and secondary dressings.



### Primary Dressing

It is recommended to use a non-adherent petrolatum or silicon-based dressing (e.g. Xeroform®, Adaptic™ or Mepitel®) (Figure 4) placed directly in contact with **Myriad** products to surrounding tissue to prevent loss and limit movement.



### Secondary Dressing

Secondary dressings, including foams, abdominal gauze (ABD) pads, NPWT or bolster dressings can be used in conjunction with **Myriad** products dependent on the level of exudate, patient factors, wound site and institutional protocols.



### Bolster Dressing

Repair of full thickness wounds, for example following tumour resections (Figure 5), may benefit from the use of a secondary bolster dressing (e.g. cotton wool, gauze) to ensure intimate contact between **Myriad** products and the underlying tissues.

Figure 5. Use of a bolster dressing to ensure approximation of **Myriad** to the underlying tissue defect.





### NPWT

**Myriad** products are compatible with standard NPWT devices. When utilising NPWT as a secondary dressing, it is important to have a non-adherent dressing placed between the **Myriad** products and the foam interface dressing. The non-adherent dressing can be placed directly over the **Myriad** products with the option to secure it in place with sutures. It is recommended that the foam interface be changed no sooner than 3-5 days to allow for adequate integration of the graft, but this is at the clinician's discretion. When implanted under an incisional closure or reconstructive tissue flap, **Myriad Matrix** is compatible with incisional NPWT.

### Dressing Changes

Dressing change frequency is determined by several factors, including;

- Which **Myriad** product was utilised (i.e. **Matrix** or **Morcells**), and the amount of **Myriad** product applied
- The amount of exudate
- Institutional and clinical guidelines
- The size and depth of the soft tissue defect



The use of **Myriad** products should not increase the frequency of dressing changes.

### Dressing Change Guidance



It is important to ensure the **Myriad** device remains adequately hydrated between dressing changes. The first dressing change is recommended between days 5-7.

At the scheduled dressing change, carefully remove the secondary and primary dressings to avoid disrupting **Myriad** in the wound bed.



Consider leaving the primary dressing in place for the initial 10-14 days to minimise interference with incorporation of the **Myriad** devices.

If portions of **Myriad** adhere to the primary dressing, add saline to hydrate and loosen the adherent material.



**Moisture retention:** A moist wound environment is important for wound healing and soft tissue repair. Always ensure **Myriad** products are fully rehydrated prior to use in either implant or dermal repair procedures. Where moisture retention is a potential concern, consider using a moistened alginate-based dressing placed over the non-adherent dressing. Additionally, a hydrogel may be added to the surface of the **Myriad** product, or on top of the primary dressing.




## What to Expect on Placement of the Device

**Myriad Matrix** and **Myriad Morcells** absorb blood and blood components once placed in contact with the tissue defect. Absorption of blood and blood components will be visible on placement of the device (Figure 6).

Figure 6. Appearance of **Myriad** products on application to the soft tissue defect.




Trans metatarsal amputation.



Scalp tumour resection.



Axilla resection.



Hip trauma defect

### Device Appearance and Integration in a Soft Tissue Defect

**Myriad** products incorporate into the wound bed over time as the devices provide a scaffold for new tissue formation.

The rate of incorporation is dependent on several factors such as the form and thickness of the **Myriad** device used, patient factors and site of the tissue deficit. Typically, buds of granulation tissue will be visible by 7-14 days as the device begins to integrate into the newly formed tissue (Figure 7).



**Allow time for the device to incorporate.** Tissue repair takes time, especially in instances of full thickness injuries, or significant volumetric tissue loss. Patience is required during the early stage of healing (<14 days) as the patient's cells populate the **Myriad** scaffold and begin the tissue repair process.

### Early Timepoints (<14 days)

Figure 7. **Myriad** products at early (<14 days) timepoints.







Figure 7 (Continued from previous page). **Myriad** products at early (<14 days) timepoints.





### Later Timepoints (>14 days)


Over time the extent of newly formed tissue will increase as **Myriad** products become fully incorporated into the newly formed tissue (Figure 8).

As **Myriad** incorporates into a soft tissue defect, it can be observed as a caramel or cream-coloured residue.

**This is normal and residual Myriad should not be removed.** An odour may be observed at the dressing change.

### Residual Myriad

Figure 8. **Myriad** products at later (+14 days) timepoints







The presence of residual **Myriad** and/or an odour do not necessarily signify an infection in isolation of the established clinical signs and symptoms of infection.

It is important to leave residual **Myriad** in place for the following reasons:

- As a mimic of tissue ECM, **Myriad** helps facilitate various cellular processes that occur during healing.<sup>[9, 10]</sup> Like tissue ECM, **Myriad** devices may also undergo degradation by tissue proteases.
- If **Myriad** is degraded by tissue proteases, a caramel or cream-coloured residue may form that has a similar appearance and odour to slough. This is expected as both slough and residual **Myriad** comprise enzymatically digested ECM fragments.
- An important difference is that residual **Myriad** contains ECM components that aid healing and modulate inflammation.<sup>[11, 12]</sup>
- Residual **Myriad** will continue to facilitate building new tissue as it incorporates and is remodeled into the wound bed.
- The rate of incorporation will vary between wounds. It is important to leave residual **Myriad** in place unless a complication is suspected.

### **Myriad persists in the wound bed to help facilitate growth of vascular, organised and functional tissue.**

- Contains >150 ECM proteins known to be important in healing.<sup>[11]</sup>
- Residual vascular channels that aid in the establishment of new vasculature.<sup>[13]</sup>
- Facilitates functional tissue by providing the natural structure of an ECM bioscaffold.<sup>[10]</sup>



Repeat applications of **Myriad** products are generally not required. However, large volumetric defects with significant depth may benefit from additional **Myriad** applications to ensure adequate tissue infill.

### Moist Wound Environment

It is important to keep **Myriad** products hydrated to ensure optimised healing. If the **Myriad** device appears dry or hardened with a yellow/brown colour (Figure 9), rehydrate with saline or hydrogel. A hydrogel may be applied over the primary dressing every 2-3 days. If the device appears adequately hydrated, consider extending the dressing change to 5-7 days.


Figure 9. Examples that need hydrating.



### Myriad Morcells may Persist in the Wound Bed

Powdered ECM or collagen products are typically re-applied every 3-7 days as they are rapidly absorbed into the tissue bed. Depending on levels of inflammation and concentrations of associated tissue proteases, **Myriad Morcells** may persist for up to 14 days (Figure 10). **Morcells** that are still visible in the wound bed at the dressing change may be left in place so that the ECM components can continue to aid healing.

Figure 10. Appearance of **Morcells** in the wound bed.



## Debridement During the Course of Myriad Healing

During the course of healing and during dressing changes, the surface of the **Myriad** devices may be gently debrided to remove any non-adherent ECM material. However, care should be taken to not remove any adherent portions of the **Myriad** products that have yet to incorporate. These areas are easily identified by the white-cream appearance of the **Myriad** products (Figure 11). Well vascularised granulation tissue is often noted if non-adherent portions of the product are debrided from the surface.

Figure 11. Debridement during the course of **Myriad** healing.



## Definitive Closure

Once a robust bed of well vascularised granulation tissue has been established in the wound bed, definitive closure may be achieved either via a split thickness skin graft, or closure via secondary intention. Definitive closure is at the surgeon's discretion taking into account patient factors and institutional guidelines. If the dermal defect is to be closed via secondary intention, consider **Endoform™** products to facilitate epithelialization.



### Bibliography

1. Solanki, N.S., et al., *A consecutive case series of defects reconstructed using NovoSorb™ Biodegradable Temporising Matrix: Initial experience and early results*. J Plast Reconstr Aesthet Surg, 2020. 73(10): p. 1845-1853.
2. Gonzalez, S.R., K.G. Wolter, and J.C. Yuen, *Infectious Complications Associated with the Use of Integra: A Systematic Review of the Literature*. Plast Reconstr Surg Glob Open, 2020. 8(7): p. e2869.
3. Rodriguez Collazo, E.R., C.R. Rathbone, and B.R. Barnes, *A Retrospective Look at Integrating a Novel Regenerative Medicine Approach in Plastic Limb Reconstruction*. Plast Reconstr Surg Glob Open, 2017. 5(1): p. e1214.
4. Chaffin, A.E. and M.C. Buckley, *Extracellular matrix graft for the surgical management of Hurley stage III hidradenitis suppurativa: a pilot case series*. J Wound Care, 2020. 29(11): p. 624-630.
5. Chaffin, A.E., et al., *Surgical reconstruction of pilonidal sinus disease with concomitant extracellular matrix graft placement: a case series*. J Wound Care, 2021. 30(Sup7): p. S28-S34.
6. Bohn, G.A. and A.E. Chaffin, *Extracellular matrix graft for reconstruction over exposed structures: a pilot case series*. J Wound Care, 2020. 29(12): p. 742-749.
7. Belkin, N.L., *Bacterial penetration vis-a-vis lint generation*. J Hosp Infect, 2002. 52(4): p. 315-7.
8. Practitioners, R.A.C.o.G., *Infection prevention and control standards. For general practices and other office-based and community-based practices*. 5 ed. May 2014, East Melbourne, Victoria, Australia.
9. Lun, S., et al., *A functional extracellular matrix biomaterial derived from ovine forestomach*. Biomaterials, 2010. 31(16): p. 4517-29.
10. Irvine, S.M., et al., *Quantification of in vitro and in vivo angiogenesis stimulated by ovine forestomach matrix biomaterial*. Biomaterials, 2011. 32(27): p. 6351-61.
11. Dempsey, S.G., et al., *Functional Insights from the Proteomic Inventory of Ovine Forestomach Matrix*. J Proteome Res, 2019. 18(4): p. 1657-1668.
12. Negron, L., S. Lun, and B.C.H. May, *Ovine forestomach matrix biomaterial is a broad spectrum inhibitor of matrix metalloproteinases and neutrophil elastase*. Int Wound J, 2012. 11(4): p. 392-397.
13. Smith, M.J., et al., *Further structural characterization of ovine forestomach matrix and multi-layered extracellular matrix composites for soft tissue repair*. J Biomater Appl, 2021. 36(6): p. 996-1010.

### RX Only.

Prior to use, be sure to read the entire Instructions For Use package insert supplied with the product. Consult your local sales representative for country specific information.



Xeroform®, Adaptic™ and Mepitel® are trademarks and property of their respective owners.

ARO A™, Myriad Matrix™, Myriad Morcells™, Endoform™ and ARO A ECM™ are trademarks of Aroa Biosurgery Limited.

MKT.1961.02 | ©June 2023